Stool DNA Test Beats Existing Noninvasive Screen for Colorectal Cancer

In a side-by-side comparison, a noninvasive, multitarget stool DNA test proved to be more sensitive than a fecal immunochemical test (FIT). This result, published March 19 in the New England Journal of Medicine, suggests that the DNA test, which includes quantitative molecular assays for genetic abnormalities related to cancer, could significantly improve the effectiveness of colon cancer screening.

The FIT test detects hidden blood in the stool, a potential signal for cancer. In contrast, the DNA test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, and β-actin, plus a hemoglobin immunoassay.

The effectiveness of the DNA test was established in a study that evaluated nearly 10,000 asymptomatic patients who were deemed to be at average risk of developing colorectal cancer. It turned out that 65 (0.7%) of these patients had colorectal cancer, and 757 (7.6%) had advanced precancerous lesions. When these patients were screened, the study determined that the sensitivity for detecting colorectal cancer was 92.3% with DNA testing and 73.8% with FIT.Stool DNA Test Beats Existing Noninvasive Screen for Colorectal Cancer

via GEN | News Highlights:Stool DNA Test Beats Existing Noninvasive Screen for Colorectal Cancer.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s